NASDAQ:VIRI

Virios Therapeutics (VIRI) Stock Forecast, Price & News

$1.02

-0.05 (-4.67%)

(As of 09/20/2023 ET)

Compare

Today's Range: $0.96
▼
$1.07
50-Day Range: $0.86
▼
$2.42
52-Week Range: $0.22
▼
$2.42

Volume: 217,500 shs
Average Volume: 271,886 shs
Market Capitalization: $19.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Virios Therapeutics MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
2.42% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.10
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$51,186 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.34) to ($0.33) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

602nd out of 962 stocks

Pharmaceutical Preparations Industry

274th out of 448 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Virios Therapeutics.

5.0

Short Interest

Percentage of Shares Shorted
2.42% of the outstanding shares of Virios Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Virios Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Virios Therapeutics has recently decreased by 17.87%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Virios Therapeutics does not currently pay a dividend.
Dividend Growth
Virios Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VIRI.

3.4

News and Social Media Coverage

News Sentiment
Virios Therapeutics has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Virios Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for VIRI on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
MarketBeat Follows
3 people have added Virios Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Virios Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $51,186.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
10.40% of the stock of Virios Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 10.96% of the stock of Virios Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Virios Therapeutics are expected to grow in the coming year, from ($0.34) to ($0.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Virios Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Virios Therapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Virios Therapeutics has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Virios Therapeutics (NASDAQ:VIRI) Stock

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

VIRI Price History

30 days | 90 days | 365 days | Advanced Chart

VIRI Stock News Headlines

September 18, 2023 | finance.yahoo.com

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

September 16, 2023 | americanbankingnews.com

Virios Therapeutics, Inc. (NASDAQ:VIRI) Short Interest Update

September 21, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

September 13, 2023 | americanbankingnews.com

Virios Therapeutics (NASDAQ:VIRI) Shares Down 3.2%

September 12, 2023 | finance.yahoo.com

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

August 15, 2023 | finance.yahoo.com

VIRI: Phase 3 Program in Fibromyalgia to Initiate in mid-2024…

August 14, 2023 | benzinga.com

What In The World Is Going On With Virios Therapeutics (VIRI) Stock?

August 14, 2023 | marketwatch.com

Virios Therapeutics Shares Rise 11% After Halt to At-The-Market Offering Sales

September 21, 2023 | Behind the Markets (Ad)

BREAKING: The truth about war with China

Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.

August 14, 2023 | finance.yahoo.com

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

August 12, 2023 | finance.yahoo.com

Virios Therapeutics, Inc. (NASDAQ:VIRI) Q2 2023 Earnings Call Transcript

August 10, 2023 | finance.yahoo.com

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 9, 2023 | benzinga.com

Virios Therapeutics's Earnings Outlook

August 9, 2023 | finance.yahoo.com

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

August 3, 2023 | finance.yahoo.com

Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

August 2, 2023 | msn.com

Virios Therapeutics (VIRI) Price Target Increased by 75.00% to 3.57

July 24, 2023 | finance.yahoo.com

VIRI: Encouraging Results for IMC-2 in Long COVID…

July 17, 2023 | finance.yahoo.com

Virios Therapeutics Long COVID Combo Therapy Shows Improvements: Long-COVID Impacts 65M People

July 17, 2023 | finance.yahoo.com

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

June 12, 2023 | seekingalpha.com

CCL, S and LL are among pre market gainers

May 25, 2023 | finance.yahoo.com

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 16, 2023 | finance.yahoo.com

VIRI: Ready to Move IMC-1 Into Phase 3 Program…

May 15, 2023 | finance.yahoo.com

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

May 12, 2023 | marketwatch.com

10-Q: VIRIOS THERAPEUTICS, INC.

May 12, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Virios Therapeutics (VIRI)

May 11, 2023 | benzinga.com

Recap: Virios Therapeutics Q1 Earnings

May 11, 2023 | finance.yahoo.com

Virios Therapeutics Announces First Quarter 2023 Financial Results

See More Headlines

Receive VIRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VIRI Company Calendar

Last Earnings: 8/10/2023
Today: 9/20/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VIRI
CUSIP: N/A
CIK: 1818844
Web: www.virios.com
Phone: 866-620-8655
Fax: N/A
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,250,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -111.40%
Return on Assets: -97.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.02
Quick Ratio: 10.02

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.88 per share
Price / Book: 1.16

Miscellaneous

Outstanding Shares: 19,247,000
Free Float: 17,245,000
Market Cap: $19.63 million
Optionable: Not Optionable
Beta: 1.95

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Gregory Duncan (Age 58)
Chairman & CEO
Comp: $559.59k

Dr. William L. Pridgen M.D. (Age 62)
Founder & Director
Comp: $35k

Ms. Angela Walsh (Age 56)
CFO, SVP of Fin., Corp. Sec. & Treasurer
Comp: $281.28k

Dr. R. Michael Gendreau M.D. (Age 67)
Ph.D., Chief Medical Officer
Comp: $420.64k

Mr. Ralph D. Grosswald M.P.H. (Age 54)
Sr. VP of Operations

Ms. Carol Duffy Ph.D.
Chief Scientific Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VIRI Stock - Frequently Asked Questions

How have VIRI shares performed in 2023?: Virios Therapeutics' stock was trading at $0.2360 on January 1st, 2023. Since then, VIRI shares have increased by 332.2% and is now trading at $1.02.
View the best growth stocks for 2023 here.
Are investors shorting Virios Therapeutics?: Virios Therapeutics saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 465,100 shares, a decline of 17.9% from the August 15th total of 566,300 shares. Based on an average trading volume of 688,600 shares, the days-to-cover ratio is presently 0.7 days.
View Virios Therapeutics' Short Interest.
When is Virios Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our VIRI earnings forecast.
How were Virios Therapeutics' earnings last quarter?: Virios Therapeutics, Inc. (NASDAQ:VIRI) posted its earnings results on Thursday, August, 10th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01.
When did Virios Therapeutics IPO?: (VIRI) raised $30 million in an initial public offering (IPO) on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

What is Virios Therapeutics' stock symbol?: Virios Therapeutics trades on the NASDAQ under the ticker symbol "VIRI."
Who are Virios Therapeutics' major shareholders?: Virios Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.80%), State Street Corp (0.29%), Citadel Advisors LLC (0.18%), McCollum Christoferson Group LLC (0.17%), Belvedere Trading LLC (0.10%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Angela Walsh, Gregory Scott Duncan, Richard James Whitley and William Pridgen.
View institutional ownership trends.
How do I buy shares of Virios Therapeutics?: Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Virios Therapeutics' stock price today?: One share of VIRI stock can currently be purchased for approximately $1.02.
How much money does Virios Therapeutics make?: Virios Therapeutics (NASDAQ:VIRI) has a market capitalization of $19.63 million. The company earns $-12,250,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.
How can I contact Virios Therapeutics?: The official website for the company is www.virios.com. The company can be reached via phone at 866-620-8655 or via email at ir@virios.com.

This page (NASDAQ:VIRI) was last updated on 9/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial